COGT Cogent Biosciences
- 7.540
- +0.010+0.13%
Cogent Biosciences News
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH)
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $20
Cogent Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)
Cogent Biosciences Analyst Ratings
Cogent Downgraded at Baird on Rare Disease Drug Data
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14
Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Cogent Biosciences Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)
Cogent Biosciences Analyst Ratings
Analysts' Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cogent Biosciences (COGT)
Buy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market Potential
Buy Rating Affirmed on Cogent Biosciences Amid Positive Outlook for Bezuclastinib's Efficacy and Safety
Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib With Strong Upside Potential
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Cogent Biosciences (COGT)
Cogent Biosciences Analyst Ratings
Cogent Biosciences: A Balanced Buy Rating Ahead of Key Data Release
Citi Initiates Coverage of Cogent at Buy, Sees Bezuclastinib Potential
Analysis
Price Target
No Data
